Ivermectin Nasal Spray Effective Against COVID-19

In a pre-clinically study, researchers in Argentina have demonstrated the safety and pharmacokinetic performance of a new nasal spray formulation designed to suppress the replication of SARS-CoV-2. Administration of ivermectin in the nasopharyngeal tissue attained high concentrations of the drug. In the current study, ivermectin spray was found to be safe and well-tolerated in pigs. Ivermectin is already being used for a decade for scabies and helminthiases. SARS-CoV-2 typically colonizes in the nasopharynx tissue.

Nasal administration would deposit the drug in the upper respiratory pathway exposing the virus to a high concentration of the drug. Over recent years, ivermectins antibacterial and antiviral activities have been observed experimentally. In this study, single or double doses of ivermectin spray (2 mg, 1 puff/nose) or oral tablets 0.2mg/kg were evaluated in pigs. Ivermectin revealed no systemic adverse effects over the entire study period. Following nasal administration, the highest concentration of drug was found in the lung tissue. A second dose of the ivermectin spray increased its concentration significantly.  

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.biorxiv.org/content/10.1101/2020.10.23.352831v1